secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-09-01T23:59:59+00:00
Accession:  0001104659-23-097500
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Carisma Therapeutics Reports Phase 1 CT-0508 Data Showing Safety and Biomarker Correlation
--------------------------------------------------------------------------------

- CT-0508 is a HER2-targeted CAR-M therapy for HER2 overexpressing cancers; 14 patients treated across group 1 (n=9) and group 2 (n=5).
- Group 1: best overall response of stable disease in 4 of 9 patients; group 2: best overall response was progressive disease.
- No dose-limiting toxicities reported; CT-0508 well-tolerated after single-day bolus infusion in group 2.
- Translational analyses combining groups show correlation between TME activation, T cell activation, and HER2 status with stable disease.
- Company to focus on combination sub-study with pembrolizumab due to T cell exhaustion findings from trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/0001104659-23-097500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000110465923097500/tm2325287d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-097500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer